What makes cancer stem cell markers different?
Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers? A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers. Glycosylation may provide the key.
['Karsten|Uwe|U|', 'Goletz|Steffen|S|']
Cancer stem cells Stem cells Therapeutic targets Glycosylation Thomsen-Friedenreich antigen